1.5 Million Euro Extra for Infection Control Scale-up LipoCoat
Series A Funding & Lab Opening
Jasper van Weerd
April 15, 2020
Introduction
LipoCoat receives €1.5 million additional funding to accelerate market entry for infection control innovations. €1.5 Million Infection Control InvestmentFunding provided by Dutch informal investors, High Tech Fund Enschede, and Innovation Fund Rabobank allows LipoCoat to open its dedicated lab at Kennispark Twente and accelerate contact lens and catheter market entry.
€1.5 Million Infection Control InvestmentFunding provided by Dutch informal investors, High Tech Fund Enschede, and Innovation Fund Rabobank allows LipoCoat to open its dedicated lab at Kennispark Twente and accelerate contact lens and catheter market entry.
Jasper van Weerd
CEO / Founder
Jasper van Weerd is CEO of Lipocoat Group and founder of the LipoCoat® coating technology, translating lipid-based science into products that improve the safety, comfort and performance of medical devices.
Follow our growth journey
Learn more about our funding, research milestones, and plans to scale infection-control innovations.
